Genmab — September 2022
-
-
-
-
Korrekt JKY: pr. 30/6 blev guide hævet til 6,8 fra 6,4
-
Genmab A/S has published its Articles of Association
https://proinvestor.com/investornyt/883051/genmab-a-s-has-published-its-articles-of-association -
Seagen, LAVA enter deal for bispecific T-cell engager targeting EGFR tumours https://firstwordpharma.com/story/5656479 LAVA x1.5 pre-market
-
USA/lukning: Plus vendt til minus efter tom melding fra England - NY
https://www.proinvestor.com/investornyt/883432/usa-lukning-plus-vendt-til-minus-efter-tom-melding-fra-england-ny -
Godmorgen.
-
Godmorgen.
-
Dine bedste venner på aktiemarkedet er tålmodighed og tid. https://www.proinvestor.com/boards/106394
-
Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK
(tisotumab vedotin-tftv) https://www.globenewswire.com/news-release/2022/09/27/2523255/0/en/Seagen-and-Zai-Lab-Announce-Regional-Strategic-Collaboration-and-License-Agreement-for-TIVDAK-tisotumab-vedotin-tftv.html -- Zai Lab Obtains Exclusive Rights to Develop and Commercialize TIVDAK in Mainland China, Hong Kong, Macau, and Taiwan --
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind